Microbiological Evaluation of Novel Bis-Quaternary Ammonium Compounds: Clinical Strains, Biofilms, and Resistance Study

Nikita Frolov 1, Elena Detusheva 2, Nadezhda Fursova 2, Irina Ostashevskaya 1,3 and Anatoly Vereshchagin 1,*

1 N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prospect 47, 119991 Moscow, Russia; nfrolov@ioc.ac.ru (N.F.); ostashevskaia@ioc.ac.ru (I.O.)
2 State Research Center for Applied Microbiology and Biotechnology, Obolensk, 142279 Serpukhov, Moscow Region, Russia; DetushevaEV@obolensk.org (E.D.); fursova@obolensk.org (N.F.)
3 Faculty of Chemistry, Moscow State University, Leninskie Gory 1, 119991 Moscow, Russia
* Correspondence: vereshchagin@ioc.ac.ru

Abstract: This work is devoted to the investigation of biocidal properties of quaternary ammonium compounds (QACs) based on pyridine structures with aromatic spacers, and their widely known analogs, against clinically significant microorganisms. This study is focused on investigating their antimicrobial activity (minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs)), antibiofilm properties (minimum biofilm inhibitory concentrations (MBICs) and minimum biofilm eradication concentrations (MBECs)), synergetic effect with different alcohols in antiseptic formulations, and bacterial resistance development. It was shown that all combined analogue preparations had a higher level of antibacterial activity against the tested bacterial strains, with a 16- to 32-fold reduction in MICs and MBCs compared to previously used antiseptic preparations. Moreover, hit-QACs demonstrated a stable effect against Gram-negative E. coli, K. pneumoniae, and A. baumannii within a month of incubation. Overall results indicated a high level of antibacterial activity of pyridine-based QACs.

Keywords: quaternary ammonium compounds; antiseptics; disinfectants; biocides; pyridinium salts; antibacterial activity; antibiofilm activity; bacterial resistance

1. Introduction

In recent years, the world has been threatened by the spread of infectious diseases due to ever-increasing pathogenic microorganisms’ resistance to widely used antibacterial drugs [1]. The treatment of infections associated with biofilms is especially difficult. Bacteria in biofilms are known for higher survival rate in the presence of aggressive substances, immune defense factors, and antibacterial drugs compared to free-floating planktonic cells [2,3]. Therefore, standard antibiotic treatment can only destroy planktonic cells without affecting attached forms, which can survive in biofilms and multiply when treatment is completed [4]. It is necessary to use large doses of expensive drugs for a long time in order to achieve bactericidal concentrations of antibiotics during the treatment of such infections. The main drawback is a significant risk of various side effects.

One of the ways to solve the problem is developing new drugs with targeted local antimicrobial activity—modern antiseptic drugs. Nowadays, the most promising components of antiseptics are quaternary ammonium compounds (QACs). Currently, QACs have a wide range of applications: they are used as therapeutic and prophylactic antiseptics, preservatives for medications and cosmetics, disinfectants and surface clearances, deodorants, etc. [5]. These compounds have high activity rate against a wide range of pathogens, such as bacteria, fungi, and some viruses. Along with an antimicrobial effect, QACs can be used as detergents, which allows combining disinfection with cleaning. They
are not volatile and are not dangerous when inhaled [6]. QACs belong to the class of cationic biocides [7]. The main target of their action is the bacterial lipid bilayer [5]. However, the nature of QACs’ mechanism is a matter of speculation [8]. Thus, QAC-based disinfectants have low toxicity, good detergent properties, and high bactericidal efficacy against Gram-positive and Gram-negative bacteria.

A significant number of QACs have been obtained throughout the last century [9,10]. At the same time, the practical use of QAC-based disinfectants requires constant epidemiological and microbiological monitoring due to microbial adaptation [11–14]. In this regard, the requirement for development of new highly active chemical compounds and microbiological investigations increases. Previously, we published several articles about the discovery of new highly active bis-pyridinium QACs with aromatic spacers (Figure 1) [15,16]. Hit compounds showed great inhibitory activity against a broad spectrum of planktonic bacteria and fungi. In this study, we expanded microbiological research of our most active QACs. Thus, QACs were tested on clinical multi-resistant strains (including research of resistance development), and bacterial biofilms. Moreover, new antiseptic compositions have been developed using combinations of novel QACs and different alcohols. Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) as well as minimum biofilm inhibitory concentrations (MBICs) and minimum biofilm eradication concentrations (MBECs) were estimated for all tested samples.

![Hit compounds from previous study](image)

![Reference commercial QACs](image)

Figure 1. Tested bis-QACs: hit compounds 1–2 from ref. [15], and 3 from ref. [16].

2. Results and Discussion

2.1. Intensity of Biofilm Formation

The ability to form biofilms was estimated for each bacterial strain. The intensity of biofilm formation was determined by density analysis. According to the results, bacterial strains were divided into two categories: the strains with a high rate of biofilm formation \((n = 6)\) and those with a modest one \((n = 4)\). Worth noting is that clinical pathogens were more prone to forming biofilms. Thus, four out of five clinical strains showed a high \(OD_{590}\) intensity, which was more than 4 times greater compared to the control strain (Tables 1 and 2).

Table 1. Intensity of biofilm formation by reference strains.

| Strains                  | OD<sub>590</sub>       | Intensity |
|--------------------------|------------------------|-----------|
| E. coli ATCC 25922       | 0.272 ± 0.011          | modest    |
| K. pneumoniae ATCC 700603| 0.255 ± 0.008          | modest    |
| S. aureus ATCC 43300     | 0.301 ± 0.008          | modest    |
| P. aeruginosa ATCC 27853 | 0.383 ± 0.013          | high      |
| A. baumannii ATCC 15308  | 0.391 ± 0.005          | high      |
Table 2. Intensity of biofilm formation by clinical strains.

| Strains            | OD<sub>590</sub> | Intensity |
|--------------------|------------------|-----------|
| E. coli B-3421/19  | 0.287 ± 0.005    | modest    |
| K. pneumonia B-2523/18 | 0.399 ± 0.011 | high      |
| S. aureus B-8648   | 0.343 ± 0.022    | high      |
| P. aeruginosa B-2099/18 | 0.452 ± 0.018 | high      |
| A. baumannii B-2996/18 | 0.415 ± 0.012 | high      |

2.2. Antibacterial Activity of Tested QACs

At first, we re-examined previously obtained hit compounds 1–3 with a suspension method and got different results from our studies in collaboration with CO-ADD (Institute for Molecular Bioscience, Brisbane, Australia) [15,16]. Modern popular commercial QACs (benzalkonium chloride (BAC), cetylpyridinium chloride (CPC), and octenidine dichloride (OCT)) were used as reference compounds (Figure 1). Detailed information on the experimental procedures and bacterial strains used is represented in the experimental section.

The microbiological study showed that all tested QACs 1–3 had a high level of antibacterial activity against Gram-positive and Gram-negative planktonic bacteria with slightly different MIC from previous research (Table 3). However, this did not oppose the general picture.

Table 3. Antibacterial activity of new bis-QACs against planktonic cells and biofilms.

| Compounds | MIC/MBC (mg/L) |
|-----------|----------------|
|           | Reference Strains | Clinical Strains |
|           | Sa | Ec | Kp | Ab | Pa | Sa | Ec | Kp | Ab | Pa |
| Planktonic cells | | | | | | | | | | |
| 1: n = 9, Br | 0.5 | 4 | 8 | 16 | 16 | 0.5 | 4 | 4 | 16 | 16 |
| 2: n = 10, Br | 1 | 8 | 16 | 16 | 16 | 1 | 8 | 16 | 32 | 250 |
| 3: n = 10, Br | 1 | 8 | 16 | 16 | 16 | 1 | 8 | 16 | 32 | 250 |
| BAC | 125 | 4 | 500 | 8 | 16 | 32 | 250 | 4 | 125 | 500 |
| CPC | 16 | 8 | 32 | 125 | 500 | 2 | 8 | 8 | 16 | 32 |
| OCT | 0.5 | 0.5 | 4 | 32 | 8 | 0.5 | 2 | 2 | 32 | 32 |
| Biofilms | | | | | | | | | | |
| 1: n = 9, Br | 8 | 16 | 16 | 32 | 125 | 8 | 16 | 16 | 32 | 125 |
| 2: n = 10, Br | 16 | 16 | 32 | 125 | 500 | 8 | 32 | 16 | 32 | 250 |
| 3: n = 10, Br | 16 | 16 | 32 | 125 | 500 | 8 | 32 | 16 | 32 | 250 |
| BAC | >500 | 250 | >500 | 250 | >500 | >500 | >500 | >500 | >500 | >500 |
| CPC | 16 | 16 | 32 | 125 | 500 | 8 | 125 | 63 | 250 | 500 |
| OCT | 4 | 8 | 16 | 250 | 125 | 4 | 125 | 63 | 250 | 250 |
The vast majority of the tested biofilms were more resilient to the studied compounds than the same bacterial strains in planktonic form (Table 3). Apparently, this was caused by the influence of different factors and characteristics of bacterial biofilms—the presence of an extracellular matrix [17], properties of substrate in which biofilms are formed [2], and production of resistance genes in biofilms [4,18]. The highest level of resistance was noted for *A. baumannii* and *P. aeruginosa*. This can be justified by specific features of these bacterial strains and it is consistent with the results of our previous studies [19]. It should be noted that Gram-positive *S. aureus* were more sensitive to the studied QACs than Gram-negative bacteria. Commercial mono-QAC BAC had extremely low rate of antibacterial activity against bacterial strains, in both planktonic (Table 2) and biofilm (Table 3) forms. For OCT, high antibacterial activity against planktonic cells was noted (Table 2). However, OCT showed a much lower level of biocide action against biofilms. Surprisingly, the activity of the studied compounds against clinical strains did not differ much from the reference cultures, and in some cases was even more expressed. Overall, the effectiveness of new bis-QACs 1-3 was higher than the effectiveness of reference antiseptics BAC and CPC and was relatively comparable to OCT (Table 2).

### 2.3. Antiseptic Compositions

Next, we investigated the combined effect of new QACs with various alcohols in antiseptic compositions. Alcohols are widely known as antibacterial agents. Those are used in many antiseptics and disinfectants as active substances [20], in cosmetic products as preservatives [21], etc. Alcohol-based hand sanitizers are recommended by WHO as preventive measures against COVID-19 [22]. Moreover, some studies report the increase in antibacterial activity when usage of biocides and alcohols is combined [23–25].

We chose isopropyl alcohol, propyl alcohol, and phenoxyethanol for various biocidal formulations. The first two are the most popular on the market and phenoxyethanol is used in combination with OCT, which is the antiseptic of choice for wound treatment according to European guidelines [26]. We prepared the following formulations: (1) QAC + phenoxyethanol/water (2% v/v solution) by analogy with the drug “Octenisept” (Schülke & Mayr) – PhE; (2) QAC + isopropyl alcohol/water (63.5% v/v solution) – IPA; (3) QAC + isopropyl alcohol/propyl alcohol/water (1:2:2 by volume) – IPAP. OCT and BAC were used as standards in the same formulations. “Empty” (without QACs) compositions were used as control samples (Tables 4 and 5).

**Table 4.** Antibacterial activity of QACs with different alcohols against planktonic cells.

| Compositions | MIC/MBC (mg/L) |
|--------------|----------------|
| PhE 1:       |                |
| n = 9, Br    |                |
| PhE 2:       |                |
| n = 10, Br   |                |
| PhE 3:       |                |
| n = 10, Br   |                |
| PhE BAC      |                |
| PhE OCT      |                |
| PhE H₂O (control) |          |
| Reference Strains |            |
| *Sa* | *Ec* | *Kp* | *Ab* | *Pa* | *Sa* | *Ec* | *Kp* | *Ab* | *Pa* |
| 2    | 2    | 4    | 8    | 16   | 2    | 2    | 2    | 16   | 16   |
| 4    | 2    | 8    | 8    | 16   | 4    | 2    | 4    | 16   | 16   |
| 2    | 2    | 2    | 8    | 16   | 2    | 4    | 4    | 16   | 16   |
| 4    | 2    | 4    | 16   | 32   | 4    | 4    | 4    | 16   | 63   |
| 2    | 2    | 4    | 8    | 16   | 2    | 4    | 8    | 16   | 16   |
| 4    | 4    | 4    | 16   | 16   | 4    | 4    | 16   | 16   | 16   |
| 4    | 16   | 16   | 16   | 32   | 1    | 16   | 32   | 16   | 16   |
| 1    | 2    | 2    | 2    | 1    | 2    | 2    | 4    | 2    | 2    |
| 8    | 2    | 1    | 2    | 2    | 8    | 4    | 4    | 8    | 8    |
| 125  | 32   | 63   | 16   | 16   | 250  | 63   | 125  | 16   | 32   |
| 500  | 32   | 125  | 125  | 125  | 500  | 63   | 250  | 125  | 125  |

**Table 5.** Antibacterial activity of PhE with different alcohols against biofilm cells.
Table 4. Cont.

| Compositions | MIC/MBC (mg/L) | Reference Strains | Clinical Strains |
|--------------|----------------|-------------------|------------------|
|              | Sa  | Ec  | Kp  | Ab  | Pa  | Sa  | Ec  | Kp  | Ab  | Pa  |
| IPA 1: n = 9, Br | 1   | 2   | 2   | 2   | 2   | 2   | 2   | 2   | 2   | 2   |
| IPA 2: n = 10, Br | 1   | 2   | 2   | 2   | 4   | 1   | 2   | 2   | 4   | 2   |
| IPA 3: n = 10, Br | 1   | 2   | 2   | 2   | 2   | 2   | 2   | 2   | 2   | 2   |
| IPA BAC | 4   | 8   | 4   | 8   | 32  | 1   | 16  | 32  | 16  | 16  |
| IPA OCT | 1   | 4   | 1   | 2   | 1   | 0.5 | 4   | 2   | 1   | 2   |
| IPA/H2O (control) | 63  | 32  | 32  | 16  | 16  | 63  | 32  | 16  | 32  | 16  |
| IPA 1: n = 9, Br | 2   | 2   | 2   | 0.5 | 8   | 2   | 2   | 4   | 4   | 8   |
| IPA 2: n = 10, Br | 2   | 2   | 2   | 2   | 2   | 2   | 4   | 2   | 4   | 8   |
| IPA 3: n = 10, Br | 2   | 2   | 1   | 2   | 2   | 2   | 2   | 2   | 4   | 8   |
| IPAP BAC | 4   | 16  | 16  | 16  | 16  | 16  | 16  | 16  | 16  | 16  |
| IPAP OCT | 1   | 1   | 1   | 2   | 2   | 0.5 | 2   | 2   | 2   | 2   |
| IPAP/H2O (control) | 16  | 32  | 63  | 16  | 16  | 63  | 16  | 125 | 16  | 16  |

Note: Color indicates results that do not differ (or worse) from those of individual substances or control samples, i.e., formulation is not effective.

Table 5. Antibacterial activity of QACs with different alcohols against biofilms.

| Compositions | MIC/MBC (mg/L) | Reference Strains | Clinical Strains |
|--------------|----------------|-------------------|------------------|
|              | Sa  | Ec  | Kp  | Ab  | Pa  | Sa  | Ec  | Kp  | Ab  | Pa  |
| PhE 1: n = 9, Br | 2   | 8   | 16  | 250 | 63  | 4   | 4   | 63  | 125 | 63  |
| PhE 2: n = 10, Br | 2   | 16  | 32  | 250 | 63  | 4   | 4   | 63  | 125 | 125 |
| PhE 3: n = 10, Br | 2   | 16  | 32  | 125 | 63  | 4   | 4   | 63  | 125 | 125 |
| PhE BAC | 16  | 16  | 32  | 32  | 125 | 16  | 16  | 32  | 16  | 32  |
| PhE OCT | 1   | 4   | 8   | 16  | 16  | 2   | 4   | 16  | 16  | 16  |
| PhE/H2O (control) | 32  | 16  | 63  | 63  | 125 | 63  | 32  | 63  | 63  | 32  |
| IPA 1: n = 9, Br | 8   | 8   | 8   | 63  | 32  | 8   | 4   | 8   | 63  | 32  |
Based on the data obtained, a number of tendencies were noted. In most cases, we observed a biocide effectiveness increase for antiseptic formulations of new QACs (1–3) in combination with alcohols. The most active of all compositions was QACs with 63.5% (v/v) IPA (isopropanol) solution, that was slightly superior in antibacterial properties to the combination with a mixture of isopropanol and propanol-1 (IPAP). Particular attention should be paid to the considerable increase in activity against *A. baumannii* and *P. aeruginosa*, belonging to the ESCAPE pathogens group, the most common cause of nosocomial infections, highly resistant to the majority of antimicrobial drugs. The MIC on *A. baumannii* planktonic cells for IPAP 1 was 32-fold less than for individual QAC 1, and MBC was 16-fold less (Tables 2 and 4). IPAP 1 showed superior properties against *P. aeruginosa* planktonic cells and biofilms, with a 16-fold reduction in MBC against both bacterial forms. Phenoxyethanol (PhE) at the concentration used was less effective. Thus, the MIC and MBC values of new QACs did not differ from those of individual substances in ~35% of all cases. For comparison, IPA had ~15% with no biocidal rate improvement and IPAP ~22%. It is worth noting that all alcohols enhanced the effect of QACs on *S. aureus* biofilms in 99% of cases. The summary table of the overall antiseptic compositions’ efficacy is represented below (Table 6).

### Table 5. Cont.

| Compositions       | MIC/MBC (mg/L) | Reference Strains | Clinical Strains |
|--------------------|----------------|-------------------|------------------|
|                    | *Sa* | *Ec* | *Kp* | *Ab* | *Pa* | *Sa* | *Ec* | *Kp* | *Ab* | *Pa* |
| **IPA 2:**         | 4    | 16   | 32   | 16   | 4    | 4    | 16   | 16   | 32   |
| *n* = 10, Br       | 8    | 4    | 16   | 32   | 32   | 8    | 16   | 16   | 32   |
| **IPA 3:**         | 2    | 4    | 16   | 32   | 16   | 4    | 16   | 16   | 32   |
| *n* = 10, Br       | 4    | 4    | 16   | 32   | 32   | 2    | 4    | 16   | 16   |
| **IPA BAC**        | 16   | 16   | 32   | 32   | 32   | 8    | 16   | 16   | 32   |
| **IPA OCT**        | 2    | 8    | 32   | 32   | 32   | 4    | 4    | 32   | 32   |
| **IPA/H₂O (control)** | 32   | 16   | 63   | 125  | 63   | 32   | 63   | 63   | 32   |
| **IPAP 1:**        | 1    | 4    | 8    | 32   | 16   | 1    | 16   | 32   | 16   |
| *n* = 9, Br        | 2    | 4    | 16   | 63   | 63   | 4    | 4    | 32   | 32   |
| **IPAP 2:**        | 1    | 8    | 16   | 32   | 32   | 2    | 8    | 32   | 32   |
| *n* = 10, Br       | 2    | 32   | 63   | 125  | 63   | 4    | 8    | 63   | 63   |
| **IPAP 3:**        | 4    | 16   | 16   | 63   | 16   | 1    | 16   | 32   | 16   |
| *n* = 10, Br       | 4    | 16   | 16   | 63   | 63   | 4    | 4    | 32   | 32   |
| **IPAP BAC**       | 16   | 1    | 32   | 125  | 16   | 1    | 32   | 32   | 63   |
| **IPAP OCT**       | 1    | 2    | 8    | 32   | 16   | 2    | 2    | 16   | 16   |
| **IPAP/H₂O (control)** | 32   | 16   | 63   | 125  | 63   | 32   | 63   | 63   | 32   |

Note: color indicates results that do not differ (or worse) from those of individual substances or control samples, i.e., formulation is not effective.
Table 6. Effectivity of antiseptic compositions.

| Compositions | Reference Strains | Clinical Strains | Σ |
|--------------|-------------------|------------------|---|
|              | Sa    | Ec    | Kp    | Ab    | Pa    | Sa    | Ec    | Kp    | Ab    | Pa    |
| **Planktonic cells** |       |       |       |       |       |       |       |       |       |       |
| PhE          | 40%   | 80%   | 90%   | 70%   | 40%   | 20%   | 80%   | 70%   | 40%   | 70%   | 60%   |
| IPA          | 50%   | 80%   | 100%  | 100%  | 80%   | 60%   | 80%   | 70%   | 80%   | 80%   | 78%   |
| IPAP         | 50%   | 80%   | 100%  | 90%   | 80%   | 30%   | 90%   | 70%   | 90%   | 80%   | 76%   |
| **Biofilms** |       |       |       |       |       |       |       |       |       |       |       |
| PhE          | 100%  | 50%   | 70%   | 40%   | 90%   | 100%  | 100%  | 60%   | 60%   | 20%   | 69%   |
| IPA          | 90%   | 90%   | 90%   | 90%   | 80%   | 100%  | 100%  | 90%   | 100%  | 80%   | 91%   |
| IPAP         | 100%  | 70%   | 90%   | 80%   | 80%   | 100%  | 100%  | 60%   | 70%   | 50%   | 80%   |

2.4. Bacterial Resistance Study

Furthermore, we investigated formation of bacterial resistance to new QACs 1–3 and the best of the commercial antiseptics OCT. A complete description of the research methodology is presented in the experimental section. The results obtained are plotted as MBC vs. incubation time of biocides with bacterial cells. The output of the graph to a plateau corresponds to the end of the experiment and indicates the cessation of resistance development by microorganisms (Figure 2).
3. Materials and Methods

3.1. Bacterial Strains

Reference strains of microorganisms E. coli ATCC 25922, K. pneumoniae ATCC 70060, S. aureus ATCC 43300, P. aeruginosa ATCC 27853, and A. baumannii ATCC 15308 were obtained from the State Collection of Pathogenic Microorganisms (Obolensk, Russia). Clinical strains of E. coli B-3421/19, K. pneumoniae B-2523/18, S. aureus B-8648, P. aeruginosa B-2099/18, and A. baumannii B-2926/18 were isolated in the Molecular Microbiology department of the Federal Budget Institution of Science State Research Center for Applied Biotechnology and Microbiology (FBSI SRC PMB, Obolensk, Russia) from clinical samples in the investigation of infection cases in 2016–2018.

3.2. Identification of Microorganisms

Species identification of microorganisms was carried out on a MALDI-TOF Biotyper mass spectrometer (Bruker, Billerica, MA, USA). One part of daily bacterial culture was introduced into a 2 mL tube (Eppendorf, Hamburg, Germany) containing 300 µL of deion-
ized water and was triturated until a homogeneous suspension was obtained. Then, 900 µL of 96% ethanol was added and shaken. The tube was then centrifuged at 12,000 × g within 2 min. The supernatant was discarded, and the precipitate was dried in air. After drying, the precipitate was thoroughly mixed with 30 µL of 70% formic acid, incubated for 10 min at room temperature, then mixed with 30 µL of acetonitrile (Sigma-Aldrich, St. Louis, MO, USA) and incubated for another 10 min. This mixture was centrifuged at 12,000 × g for 2 min; then, 1 µL of the supernatant was transferred to a MSP 96 Polished Steel MALDI Target Plate (Bruker Daltonik GmbH, Bremen, Germany), air-dried, and covered with 1 µL of a saturated solution of α-cyano-4-hydroxycinnamic acid (Bruker Daltonik, Bremen, Germany). The MALDI target plate was placed in a MALDI-TOF microflex LRF instrument (Bruker Daltonik, Bremen, Germany). The data acquisition settings were as follows: ion source 1 at 19.50 kV, ion source 2 at 18.22 kV, lens at 7.01 kV, and a mass range of 2000 to 20,000 Da. Spectrum registration was performed automatically using the MALDI Biotyper RTC 3.1 software (Bruker Daltonik, Bremen, Germany). The obtained spectra were compared with the reference spectra of the FFL v1.0 database. Identification scores ≥2.0 and 1.7–1.99 indicated recognition of the species and genus levels, respectively, while scores <1.7 indicated a lack of reliable data.

3.3. Antibacterials

All investigated QACs were synthesized in N. D. Zelinsky Institute of Organic Chemistry Russian Academy of Sciences. Full experimental and characterization data can be found elsewhere [15,16]. Phenoxethanol and benzalkonium chloride were purchased from Acros Organics and used without further purification. Cetylpyridinium chloride was synthesized from pyridine using the simple method of alkylation in acetonitrile. Octenidine dihydrochloride was synthesized using previously described method [27]. Propanol-1 and propanol-2 were purchased from Rushim and purified using distillation.

3.4. Cultivation of Microorganisms

Microorganisms were cultivated using agar and GRM broth. Cultivation of microorganisms was carried out for 20–24 h at a temperature of 37 °C.

3.5. Determination of the Biofilm Formation Ability

The efficiency of bacterial biofilm formation was determined using a method based on the ability of the crystal violet dye to bind with cells and biofilm matrix [28]. To obtain biofilms, 96-well flat-bottomed culture plates were used. In each well, 200 µL of a daily bacterial culture was inoculated at a concentration of 10⁶ CFU/mL and cultivated for 24 h at a temperature of 37 °C. Then, the medium with planktonic cells was carefully taken from the plate. Wells with biofilms were washed for 2–3 min using sterile PBS buffer (NaCl—8 g, KCl—0.2 g, Na₂HPO₄—1.44 g, KH₂PO₄—0.24 g per 1 L, pH = 7.4) in the same volume to remove the residual planktonic cells. After washing, PBS was completely removed by pipetting. Then, 200 µL of a filtered 0.1% solution of gentian violet was added to each well, and the biofilms were incubated with the dye for 10–15 min at room temperature. The dyes were completely removed from the well by pipetting. The unbound dye was thoroughly washed off with PBS. The plates were inverted onto filter paper and dried. After complete drying of the surface, a 200 µL mixture of ethanol–isopropanol (1:1) was added to the wells. The dye was washed off from the surface of the wells, taken, and placed in clean flat-bottomed plates. The optical density of the resulting solution was measured at a wavelength of 590 nm using an xMark™ Microplate Absorbance Spectrophotometer (Bio-Rad Laboratories Inc., Hercules, CA, USA). The measurement results were interpreted by comparing the OD₅₉₀ values of the samples with control ones (pure solvent without dye added).

The absence of biofilm was recorded at OD₅₉₀ sample ≤ OD₅₉₀ control; weak degree of biofilm production at OD₅₉₀ control < OD₅₉₀ sample ≤ 2*OD₅₉₀ control; average degree of biofilm production at 2*OD₅₉₀ control < OD₅₉₀ sample ≤ 4*OD₅₉₀ control; high
degree of biofilm production at OD<sub>590</sub> control < 4*sample OD<sub>590</sub>; in accordance with the recommendations of Rodrigues et al. [29]. All experiments were carried out in triplicate.

3.6. Antibacterial Assay

MIC and MBC were determined by the suspension method. For this, two-fold dilutions of the tested solutions (500–0.25 mg/L) were prepared in nutrient broth. The nutrient broth with tested QACs (0.1 mL) was added to 12 wells in the horizontal rows of the culture plate. In separate rows, nutrient broth without QACs was added for control measures. In the case of antibiofilm analysis, nutrient broth with the appropriate concentration of the tested compounds was added in 0.1 mL to 12 wells in horizontal rows of a culture plate with washed biofilms, which were prepared according to the abovementioned method.

From single colonies grown on GRM medium at 37 °C for 18 h, a suspension was prepared with an optical density of 0.5 according to the McFarland standard in sterile saline, which corresponds to approximately 1–2 × 10<sup>9</sup> CFU/mL. The suspension was then diluted 100-fold by adding 0.2 mL of the suspension to a flask containing 19.8 mL of Mueller–Hinton broth (MHB). The concentration of microorganisms, in this case, was 10<sup>6</sup> CFU/mL. An amount of 0.1 mL of the initial suspension was added to the wells with the test drug and control wells with broth. The final concentration of the microorganisms in each well was 5 × 10<sup>5</sup> CFU/mL. The plates were covered with lids and placed in a thermostat (37 °C) for 20 h. The presence of bacterial growth was taken into account visually (according to the presence of turbidity in the well). MIC was taken to be the minimum concentration of the preparation at which bacterial growth was absent after 20 h of incubation. MBC was determined by the results of inoculation on dense nutrient media. To do this, from all the wells in which there was no visible growth (according to the presence of turbidity), 10 µL were sown on Mueller–Hinton nutrient agar. The results were taken into account by the presence of culture growth at the site of application after 24 h of incubation at a temperature of 37 °C. If there was no growth in the well, but the growth of the studied culture was observed when seeding from this well on a solid nutrient medium, then this concentration was taken as MIC. The lowest concentration was taken as MBC, at which cell growth was completely suppressed when seeded on a dense nutrient medium.

3.7. Bacterial Resistance Assay

The selection of resistant microorganisms is carried out by regular culture of the bacterial strains in a nutrient broth containing serial dilutions of the antibacterial drug. To do this, in 2 mL of nutrient broth, a series of two-fold dilutions of the drug were prepared, starting with a concentration that was half the MIC. During the initial inoculation, 20 µL of 10<sup>7</sup> CFU/mL of daily culture was added to each tube and incubated at 37 °C. After two to three days of incubation, 50 µL from the last turbid tube with a higher concentration was divided into new ones with increasing concentrations of the tested antibacterial drug. During subsequent transfers to increasing concentrations, 50 µL was also taken from the last tube, in ascending order, in which visual growth was observed. The selection process was stopped if the MBC had not changed within 6–8 passages.

4. Conclusions

Herein, we demonstrated that new pyridinium bis-QACs with aromatic spacers possessed a broader spectrum of antibacterial activity compared to the widely used commercial antiseptics benzalkonium chloride and cetlypyridinium chloride. Hit-QACs showed good bacteriostatic (MICs 0.5 mg/L for Gram-positive <i>S. aureus</i>, and 4 to 16 mg/L for Gram-negative bacteria), bactericidal (MBCs 4 mg/L for Gram-positive <i>S. aureus</i>, and 8 to 16 mg/L for Gram-negative bacteria), and promising biofilm-eradicating properties (MBECs 8 to 16 mg/L for Gram-positive <i>S. aureus</i>, and 16 mg/L for Gram-negative <i>E. coli</i>). Moreover, QACs’ biocidal properties against planktonic cells and biofilms greatly improved when used in combination with different alcohols, especially with isopropanol (effective in 78% of the cases for planktonic cells, and in 91% of the cases for biofilms). Bacterial resistance
studies showed that the new QACs had a more stable effect against Gram-negative bacteria than the modern sanitizer octenidine dichloride. Thus, QAC 1 was on the same level of MBC after the month of incubation with E. coli. In light of the obtained results, we are encouraged to continue investigations of this biocide class.

**Author Contributions:** Conceptualization, A.V. and N.F. (Nikita Frolov); methodology, A.V., N.F. (Nikita Frolov), E.D. and N.F. (Nadezhda Fursova); investigation, A.V., N.F. (Nikita Frolov), E.D., N.F. (Nadezhda Fursova) and I.O.; writing—original draft preparation, N.F. (Nikita Frolov) and E.D.; writing—review and editing, A.V. and I.O; visualization, N.F. (Nikita Frolov) and I.O.; supervision, A.V.; funding acquisition, A.V. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Russian Science Foundation (RSF grant 17-73-20260). The antimicrobial screening performed in cooperation with the Molecular Microbiology department of Federal Budget Institution of Science State Research Center for Applied Biotechnology and Microbiology (FBSI SRC PMB, Obolensk, Russia) within the framework of the industry research program of Rospotrebnadzor.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data is contained within the article.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. O’NEILL, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations; Government of the United Kingdom: London, UK, 2016; p. 84.
2. Flemming, H.-C.; Wingender, J.; Szewzyk, U.; Steinberg, P.; Rice, S.A.; Kjelleberg, S. Biofilms: An emergent form of bacterial life. Nat. Rev. Microbiol. 2016, 14, 563–575. [CrossRef] [PubMed]
3. Harriot, M.M. Biofilms and Antibiotics. In Reference Module in Biomedical Sciences; Elsevier: Amsterdam, The Netherlands, 2019. [CrossRef]
4. Hall, C.W.; Mah, T.-F. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol. Rev. 2017, 41, 276–301. [CrossRef] [PubMed]
5. Jennings, M.C.; Minbiole, K.P.C.; Wuest, W.M. Quaternary Ammonium Compounds: An Antimicrobial Mainstay and Platform for Innovation to Address Bacterial Resistance. ACS Infect. Dis. 2015, 1, 288–303. [CrossRef] [PubMed]
6. Artasensi, A.; Mazzotta, S.; Fumagalli, L. Back to Basics: Choosing the Appropriate Surface Disinfectant. Antibiotics 2021, 10, 613. [CrossRef]
7. Gilbert, P.; Moore, L.E. Cationic antiseptics: Diversity of action under a common epithet. J. Appl. Microbiol. 2005, 99, 703–715. [CrossRef]
8. Tischer, M.; Pradel, G.; Ohlsen, K.; Holzgrabe, U. Quaternary Ammonium Salts and Their Antimicrobial Potential: Targets or Nonspecific Interactions? ChemMedChem 2012, 7, 22–31. [CrossRef]
9. Bureš, F. Quaternary Ammonium Compounds: Simple in Structure, Complex in Application. Top. Curr. Chem. 2019, 377, 14. [CrossRef]
10. Vereshchagin, A.N.; Frolov, N.A.; Egorova, K.S.; Setikalieva, M.M.; Ananikov, V.P. Quaternary Ammonium Compounds (QACs) and Ionic Liquids (ILs) as Biocides: From Simple Antiseptics to Tunable Antimicrobials. Int. J. Mol. Sci. 2021, 22, 6793. [CrossRef]
11. Buffet-Bataillon, S.; Tattevin, P.; Bonnaure-Mallet, M.; Jolivet-Gougeon, A. Emergence of resistance to antibacterial agents: The role of quaternary ammonium compounds—a critical review. Int. J. Antimicrob. Agents 2012, 39, 381–389. [CrossRef]
12. Forman, M.E.; Fletcher, M.H.; Jennings, M.C.; Duggan, S.M.; Minbiole, K.P.C.; Wuest, W.M. Structure–Resistance Relationships: Interrogating Antiseptic Resistance in Bacteria with Multicationic Quaternary Ammonium Dyes. ChemMedChem 2016, 11, 958–962. [CrossRef]
13. Gerba, C.P. Quaternary Ammonium Biocides: Efficacy in Application. Appl. Environ. Microbiol. 2015, 81, 464–469. [CrossRef] [PubMed]
14. Jiao, Y.; Niu, L.-n.; Ma, S.; Li, J.; Tay, F.R.; Chen, J.-h. Quaternary ammonium-based biomedical materials: State-of-the-art, toxicological aspects and antimicrobial resistance. Prog. Polym. Sci. 2017, 71, 53–90. [CrossRef] [PubMed]
15. Vereshchagin, A.N.; Gordeeva, A.M.; Frolov, N.A.; Proshin, P.I.; Hansford, K.A.; Egorov, M.P. Synthesis and Microbiological Properties of Novel Bis-Quaternary Ammonium Compounds Based on Biphenyl Spacer. Eur. J. Org. Chem. 2019, 2019, 4123–4127. [CrossRef]
16. Vereshchagin, A.N.; Frolov, N.A.; Konyuhova, V.Y.; Hansford, K.A.; Egorov, M.P. Synthesis and microbiological properties of novel bis-quaternary ammonium compounds based on 4,4′-oxydiphenol spacer. Mendeleev Commun. 2019, 29, 523–525. [CrossRef]
17. Flemming, H.-C.; Wingender, J. The biofilm matrix. *Nat. Rev. Microbiol.* 2010, 8, 623–633. [CrossRef]
18. Roy, R.; Tiwari, M.; Donelli, G.; Tiwari, V. Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. *Virulence* 2018, 9, 522–554. [CrossRef]
19. Vereshchagin, A.N.; Frolov, N.A.; Mineeva, A.P.; Detusheva, E.V.; Derkach, Y.V.; Egorov, M.P. Synthesis and biological evaluation of novel cyanuric acid-tethered tris-pyridinium derivatives. *Mendeleev Commun.* 2021, 31, 368–369. [CrossRef]
20. Harke, H.-P. Disinfectants. In *Ullmann’s Encyclopedia of Industrial Chemistry*; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2000. [CrossRef]
21. Halla, N.; Fernandes, I.P.; Heleno, S.A.; Costa, P.; Boucherit-Otmani, Z.; Boucherit, K.; Rodrigues, A.E.; Ferreira, I.C.E.R.; Barreiro, M.F. Cosmetics Preservation: A Review on Present Strategies. *Molecules* 2018, 23, 1571. [CrossRef]
22. Abuga, K.; Nyamweya, N. Alcohol-Based Hand Sanitizers in COVID-19 Prevention: A Multidimensional Perspective. *Pharmacy* 2021, 9, 64. [CrossRef]
23. Art, G. Combination Povidone-Iodine and Alcohol Formulations More Effective, More Convenient Versus Formulations Containing Either Iodine or Alcohol Alone: A Review of the Literature. *J. Infus. Nurs.* 2005, 28, 314–320. [CrossRef]
24. Reichel, M.; Heisig, P.; Kohlmann, T.; Kampf, G. Alcohols for Skin Antiseptics at Clinically Relevant Skin Sites. *Antimicrob. Agents Chemother.* 2009, 53, 4778–4782. [CrossRef] [PubMed]
25. Thaddeus, N.I.; Francis, E.C.; Jane, O.O.; Obumneme, A.C.; Okechukwu, E.C. Effects of some common additives on the antimicrobial activities of alcohol-based hand sanitizers. *Asian Pac. J. Trop. Med.* 2018, 11, 222–226. [CrossRef]
26. Babalska, Z.L.; Korbecza-Paczkowska, M.; Karpiński, T.M. Wound Antiseptics and European Guidelines for Antiseptic Application in Wound Treatment. *Pharmaceuticals* 2021, 14, 1253. [CrossRef] [PubMed]
27. Bailey, D.M.; DeGrazia, C.G.; Hoff, S.J.; Schulemburg, P.L.; O’Connor, J.R.; Paris, D.A.; Slee, A.M. Bispyridinamines: A new class of topical antimicrobial agents as inhibitors of dental plaque. *J. Med. Chem.* 1984, 27, 1457–1464. [CrossRef]
28. O’Toole, G.A.; Kolter, R. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: A genetic analysis. *Mol. Microbiol.* 1998, 28, 449–461. [CrossRef]
29. Rodrigues, L.; Santos, L.; Tagliari, V.; Rizzo, N.; Trehago, G.; Oliveira, A.; Goetz, F.; Nascimento, V. Quantification of biofilm production on polystyrene by Listeria, Escherichia coli and Staphylococcus aureus isolated from a poultry slaughterhouse. *Braz. J. Microbiol.* 2010, 41, 1082–1085. [CrossRef]